|
Podium Session I |
HEALTH CARE DECISION-MAKER’S CASE STUDIES I |
| CASE1: |
AN INTEGRATED PILOT PROJECT UTILIZING AN INTERNAL HTA PROCESS TO SET MEDICAL AND PAYMENT POLICY IN A U.S. COMMERCIAL HEALTH PLAN
Watkins J1, Choudhury S1, Sturm L2, Bresnahan B3, Sullivan S3
1Premera Blue Cross, Mountlake Terrace, WA, USA; 2Formulary Resources, LLC, Issaquah, WA, USA; 3University of Washington, Seattle, WA, USA |
| |
| |
|
| CASE2: |
DRUG ELUTING STENTS - AN EXAMPLE OF THE TRANSITION FROM EVIDENCE TO POLICY THROUGH THE ONTARIO COMPREHENSIVE APPROACH TO THE DIFFUSION OF HEALTH TECHNOLOGIES
Levin L1, Goeree R2
1Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada; 2McMaster University, Hamilton, ON, Canada |
| |
|
| CASE3: |
GREVIEWING AND ADAPTING A LOCAL HEALTH TECHNOLOGY ASSESSMENT PROGRAM TO DEPARTMENTS WITHIN A CANADIAN HEALTH REGION
Austen L, Poulin P
Calgary Health Region, Calgary, AB, Canada |
Outcomes Research in Canada |
| CA1: |
ECONOMIC ANALYSIS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN THE PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH - A CANADIAN PERSPECTIVE
Deniz B1, Sadri H2
1United BioSource Corporation, Concord, MA, USA, 2Medtronic of Canada Ltd, Toronto, ON, Canada |
| |
|
| CA2: |
THE USE OF RESEARCH ABSTRACTS IN FORMULARY DECISION MAKING BY THE ONTARIO CANCER DRUG APPROVAL COMMITTEE
Weizman A1, Bell C2
1University of Toronto, Toronto, ON, Canada, 2Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada
|
| |
|
| CA3: |
A COST-EFFECTIVENESS ANALYSIS OF HEPATITIS C SCREENING AMONG IMMIGRANTS IN CANADA.
Chen W1, Dinner K2, Wong T2, Heathcote J3, Krahn MD3
1University of Toronto, Toronto, ON, Canada, 2Public Health Agency of Canada, Ottawa, ON, Canada, 3University Health Network, Toronto, ON, Canada |
| |
|
| CA4: |
THE EARLY CLINICAL AND ECONOMIC BENEFITS OF ATORVASTATIN IN A CANADIAN SETTING
Merikle E1, Ramos É1, Kuznik A2, Botteman MF3
1Pfizer Canada Inc, Kirkland, QC, Canada, 2Pfizer Inc, New York, NY, USA, 3PharMerit North America LLC, Bethesda, MD, USA |
Drug and Health Services Use Research |
| |
|
| DH1: |
FOLLOW-UP VISITS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER DURING INITIATION OF ANTIDEPRESSANT TREATMENT
Chen SY, Hansen R, Maciejewski ML
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
| |
| DH2: |
IMPACT OF ADHERING TO LIPID MANAGEMENT NATIONAL GUIDELINE RECOMMENDATIONS ON CARDIOVASCULAR EVENTS AND COSTS IN A MANAGED CARE POPULATION
Balu S1, Simko RJ1, Burge RT1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA |
| |
|
| DH3: |
THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL: A PATIENT-LEVEL APPROACH USING QUEBEC'S PROVINCIAL HEALTH PLAN DATA
Lichtenberg F1, Van Audenrode M2, Grootendorst P3, Latremouille-Viau D2, Lefebvre P2
1Columbia University, New York, NY, USA, 2Groupe d'analyse, Ltee, Montreal, QC, Canada, 3University of Toronto, Toronto, ON, Canada |
| |
|
| DH4: |
MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES: ANALYSIS OF NEW DRUGS APPROVED FROM 1980 TO 2007
Qureshi ZP, Szeinbach SL, Seoane-Vazquez E
The Ohio State University, Columbus, OH, USA |
Mental Health Outcomes Research |
| MH1: |
REAL WORLD ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND WEIGHT GAIN IN AN ADOLESCENT POPULATION
Ghate SR1, Said Q2, Rosenblatt LC3, Kim E3, Pikalov A4, Brixner D1
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2University of Arkansas for Medical Sciences, Little Rock, AR, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4Otsuka America Pharmaceuticals, Rockville, MD, USA |
| |
|
| MH2: |
ECONOMIC AND CLINICAL CONSEQUENCES ASSOCIATED WITH POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ANTIPSYCHOTICS AND CONCOMITANT MEDICATIONS IN PATIENTS WITH SCHIZOPHRENIA
Guo JJ1, Kelton CM1, Patel NC1, Wu JH2, Jing Y1, Fan H3, Keck P1
1University of Cincinnati, Cincinnati, OH, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Covance Inc, Sun Prairie, WI, USA |
| |
|
| MH3: |
WORK ABSENTEEISM AND BED DAYS IN CHRONIC MEDICAL DISORDER PATIENTS WITH AND WITHOUT DEPRESSION IN THE UNITED STATES, 2004-2005
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA |
| |
|
| MH4: |
TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER
Guo JJ1, Kelton CM1, Jing Y1, Patel NC2
1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA |
Research on Medicare Part D and Reimbursement Policies I |
| MD1: |
MEDICARE PART D: EARLY EVIDENCE ON PRESCRIPTION DRUG TREATMENT PATTERNS, HOSPITALIZATION OFFSETS AND MEDICARE SPENDING
Zhang Y1, Newhouse JP2, Hanlon J1, Lave J1, Donohue JM1
1University of Pittsburgh, Pittsburgh, PA, USA, 2Harvard University, Boston, MA, USA |
| |
|
| MD2: |
THE IMPACT OF MEDICARE PART D ON THE PERCENT GROSS MARGIN EARNED BY TEXAS INDEPENDENT PHARMACIES FOR DUAL ELIGIBLE BENEFICIARY CLAIMS
Winegar AL, Shepherd MD, Lawson K, Richards KM
University of Texas at Austin, Austin, TX, USA |
| |
|
| MD3: |
IMPACT OF MEDICARE PART D DOUGHNUT HOLE ON THE USE OF MEDICATIONS BY THERAPEUTIC CLASSES FOR STANDARD BENEFICIARIES
Sun SX, Lee KY
Walgreens Health Services, Deerfield, IL, USA |
| |
|
| MD4: |
IMPACT OF THE MEDICARE MODERNIZATION ACT OF 2003 ON PART B DRUG USE AND SPENDING: A CASE STUDY OF BIOLOGICALS FOR RHEUMATOID ARTHRITIS
Doshi JA, Li P, Puig A
University of Pennsylvania, Philadelphia, PA, USA |
| Podium Session II |
HEALTH CARE DECISION-MAKER’S CASE STUDIES II |
| CASE4: |
THE IMPACT OF THE PROJECT OF ENHANCING COVERAGE RATE FOR PATIENTS WITH CANCER
Reddy P1, Yeh Y1, Clapp M2, Churchill W3
1Partners Healthcare, Charlestown, MA, USA; 2 Massachusetts General Hospital, Boston, MA, USA; 3 Brigham and Women's Hospital, Boston, MA, USA |
| |
|
| CASE5: |
THE CENTER FOR DRUG POLICY: PARTNERS HEALTH CARE
Lee SM, Nam MH, Yoon SH, Kim BY, Choi MR, Cho HS, Lee KD
Health Insurance Review & Assessment Services, Seoul, South Korea |
| |
|
| CASE6: |
THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY TO IMPROVE QUALITY IN THE ACUTE CARE SETTING
Mutnick AH, Wong PK, Hanseman DJ
Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA |
Cancer Outcomes Research |
| CN1: |
TRENDS IN TREATMENT AMONG ELDERLY COLORECTAL CANCER PATIENTS IN THE US: EVIDENCE FROM LINKED SEER-MEDICARE DATA
Lang K1, Lines LM1, Lee DW2, Korn JR1, Vanness DJ3, Earle C4, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA, 2GE Healthcare, Waukesha, WI, USA, 3University of Wisconsin-Madison, Madison, WI, USA, 4Harvard University, Boston, MA, USA |
| |
|
| CN2: |
ECONOMIC EVALUATION OF EGFR-GUIDED TREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER
Carlson JJ1, Garrison L1, Ramsey S2, Veenstra DL1
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA |
| |
|
| CN3: |
COMPARISON OF THE COST EFFECTIVENESS OF SIX CYCLES OF TAXOTERE, DOXORUBICIN, CYCLOPHOSPHAMIDE (TAC) VERSUS SIX CYCLES OF FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE (FAC) IN THE ADJUVANT SETTING OF NODE POSITIVE BREAST CANCER WITH PRIMARY AND SECONDARY G-CSF PROPHYLAXIS
Mittmann N1, Koo M1, Alloul K2, Trudeau M3
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2sanofi-aventis Canada, Montreal, QC, Canada, 3Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada |
| |
|
| CN4: |
COSTS ASSOCIATED WITH NEUTROPENIA IN ELDERLY PATIENTS TREATED FIRST-LINE FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Stokes ME1, Muehlenbein CE2, Marciniak MD2, Faries D2, Motabar S3, Buesching DP2, Gillespie TW4, Lipscomb J4, Knopf KB5
1United BioSource Corporation, Dorval, QC, Canada, 2Eli Lilly and Company, Indianapolis, IN, USA, 3United BioSource, Bethesda, MD, USA, 4Emory University and Veterans Affairs Medical Center, Atlanta, GA, USA, 5California Pacific Medical Center, San Francsico, CA, USA |
Health Policy Research |
| HP1: |
A COMPARISON OF THREE TECHNOLOGY APPRAISAL SYSTEMS; NICE, SMC AND CADTH
Karia R1, Gani R2, Perard R1, Cann K2
1Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK, 2Heron Evidence Development Ltd, Hertfordshire, UK |
| |
|
| HP2: |
NHS REIMBURSEMENT OF NEW CANCER DRUGS: IS NICE GETTING NASTIER?
Mason AR1, Drummond M2
1University of York, York, N. Yorkshire, UK, 2University of York, York, Heslington, UK |
| |
|
| HP3: |
PRIORITY SETTING FOR NEW TECHNOLOGIES: POSSIBLE DETERMINANTS AMONG THE WORKING POPULATION
Derycke H, Annemans L
1Ghent University, Gent, Belgium |
| |
|
| HP4: |
25 YEARS OF THE ORPHAN DRUG ACT: ANALYSIS OF THE NEW ORPHAN DRUGS APPROVED BETWEEN 1983 AND 2007
Rodriguez-Monguio R1, Visaria J2, Seoane-Vazquez E2
1University of Massachusetts, Amherst, MA, USA, 2The Ohio State University, Columbus, OH, USA |
Research on Medicare Part D and Reimbursement Policies II |
| MD5: |
HEALTH CARE UTILIZATION BY MEDICARE ADVANTAGE BENEFICIARIES IN THE ERA OF THE MEDICARE PART D DRUG BENEFIT COVERAGE GAP
Delate T1, Raebel MA2, Ellis JL2, Bayliss EA2
1Kaiser Permanente Colorado, Aurora, CO, USA, 2Kaiser Permanente Colorado, Denver, CO, USA |
| |
|
| MD6: |
INFLUENCE OF MEDICARE CLAIM-PAYING AGENTS' REIMBURSEMENT POLICY ON G-CSF CHOICE DURING FIRST CYCLE OF CHEMOTHERAPY FOR NON-HODGKIN'S LYMPHOMA PATIENTS
Pan X1, Brooks JM2, Wright KB1, Voelker MD1
1University of Iowa, Iowa City, IA, USA, 2USRDS Economic Special Study Center, The University of Iowa, Iowa City, IA, USA |
| |
|
| MD7: |
DIFFERENTIAL TAKE-UP OF THE MEDICARE PART D PRESCRIPTION DRUG BENEFIT
Rabbani A1, Yin W1, Zhang JX1, Sun SX2, Alexander GC1
1University of Chicago, Chicago, IL, USA, 2Walgreens Health Services, Deerfield, IL, USA |
| |
|
| MD8: |
THE IMPACT OF MEDICARE NEW DRUG BENEFIT (PART D) ON THE UTILIZATION OF PSYCHOTROPIC MEDICATIONS AND CONSEQUENT OUT OF POCKET EXPENDITURE FOR ELDERLY
Chen H1, Nwangwu A1, Aparasu R1, Sun SX2, Lee KY2
1University of Houston, Houston, TX, USA, 2Walgreens Health Services, Deerfield, IL, USA |
Research on Patient Reported Outcomes Methods |
| PM1: |
RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Gu NY, Doctor JN
University of Southern California, Los Angeles, CA, USA |
| |
|
| PM2: |
WHAT PATIENTS SAY VS. WHAT PATIENTS MEAN: QUALITATIVE RESEARCH IN PRO DEVELOPMENT
Lasch KE1, Marquis P1, Vigneux M2, Abetz L3, Arnould B2, Bayliss MS1, Crawford B1, Rosa K1, Scott J1
1Mapi Values, Boston, MA, USA, 2Mapi Values, Lyon, France, 3Mapi Values Limited, Bollington, UK |
| |
|
| PM3: |
THE VALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACH TO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN
Ungar WJ1, Boydell K1, Dell S1, Feldman BM1, Marshall DA2, Willan AR1, Wright J1
1The Hospital for Sick Children, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada |
| |
|
| PM4: |
EVALUATION OF A THEORY OF GLOBAL HEALTH PREFERENCE FORMATION
Shaw JW1, Pickard AS1, Lin HW1, Cella D2, Trask PC3
1University of Illinois at Chicago, Chicago, IL, USA, 2Evanston Northwestern Healthcare, Evanston, IL, USA, 3Pfizer, Inc, New London, CT, USA |
Podium Session III |
Research in Adherence and Compliance I |
| AC1: |
THE ASSOCIATION BETWEEN IMPROVEMENTS IN DRUG ADHERENCE AND SHORT-TERM SERVICE UTILIZATION AND COSTS IN A MEDICAID POPULATION
Thiebaud P
Pfizer Health Solutions, New York, NY, USA |
| |
|
| AC2: |
PATTERNS OF DIABETES MEDICATION AND TEST ADHERENCE IN A MEDICAID DISEASE MANAGEMENT PROGRAM
Demand M, Gutierrez PR, Thiebaud P
Pfizer Health Solutions, New York, NY, USA |
| |
|
| AC3: |
DEPRESSIVE SYMPTOMATOLOGY, MEDICATION PERSISTENCE, AND ASSOCIATED HEALTH CARE COSTS IN OLDER ADULTS WITH INSOMNIA
Kulkarni AS1, Patel I2, Anderson RT3, Balkrishnan R1
1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2The Ohio State University, Columbus, OH, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA |
| |
|
| AC4: |
THE COST OF NON-ADHERENCE TO ASTHMA TREATMENT GUIDELINES AMONG A LOW-INCOME COHORT
Said Q1, Waitzman NJ2
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Utah, Salt Lake City, UT, USA |
Cardiovascular Disease Outcomes Research |
| CV1: |
EFFECTIVENESS OF COMBINED BETA-BLOCKER AND ACEI OR ARB THERAPY IN CHRONIC HEART FAILURE
Sharma M1, Deswal A2, Henderson L3, Desai R1, Chitnis A1, Petersen N4, Ashton C5, Johnson M4
1University of Houston, Houston, TX, USA, 2Baylor College of Medicine; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA, 3University of Texas M.D.Anderson Cancer Center, Houston, TX, USA, 4Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA, 5University of Alabama, Birmingham, AL, USA |
| |
|
| CV2: |
THE COST-EFFECTIVENESS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE (HF)- AN ASSESSMENT OF THE LOW LEFT VENTRICULAR EJECTION FRACTION (LOW-LVEF) TRIALS IN THE CANDESARTAN-IN-HEART-FAILURE-ASSESSMENT-OF-REDUCTION-IN-MORTALITY-AND-MORBIDITY (CHARM) TRIAL PROGRAMME
Levin LÅ1, Jørgensen E2, Eriksson B3, Swedberg K4, Paulsson T3
1Linköping University, Linköping, Sweden, 2AstraZeneca, Oslo, Norway, 3AstraZeneca, Södertälje, Sweden, 4Sahlgrenska Academy, Göteborg University, Gothenburg, Sweden |
| |
|
| CV3: |
CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLEEDING DURING CORONARY ARTERY BYPASS GRAFT SURGERY AMONG ELDERLY AMERICANS
Ganz ML1, Joshi AV2, Wang Q3, Wilke CT4, Lee WC3, Pashos CL1
1Abt Associates, Inc, Lexington, MA, USA, 2Novo Nordisk Inc, Princeton, NJ, USA, 3Abt Associates, Inc, Bethesda, MD, USA, 4University of Illinois at Chicago, Chicago, IL, USA |
| |
|
| CV4: |
CAN TWO A'S RESULT IN A FAILURE?: EFFECT OF ASPIRIN ON THE RISK OF HEART FAILURE HOSPITALIZATIONS IN CHF PATIENTS ON ACE INHIBITORS.
Shah DH, Parikh NM, Kamble PS, Chen H, Johnson M
University of Houston, Houston, TX, USA |
Diabetes Outcomes Research |
| DB1: |
REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE
Brixner D1, McAdam-Marx C1, Ye X1, Boye KS2, Schroeder B3, Fabunmi R3
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Amylin Pharmaceuticals, Inc, San Diego, CA, USA |
| |
|
| DB2: |
COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN MEXICO
Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2, Rosado-Buzzo AA2, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Funsalud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico |
| |
|
| DB3: |
REAL-WORLD ANALYSIS OF PERCENT OF PATIENTS WITH TYPE 2 DIABETES ACHIEVING GLYCEMIC GOAL WITH INSULIN GLARGINE
Misurski D1, Schroeder B2, Wade R3, Quimbo R3, Nielsen L2, Fabunmi R2, Wintle M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Amylin Pharmaceuticals, Inc, San Diego, CA, USA, 3HealthCore, Inc, Wilmington, DE, USA |
| |
|
| DB4: |
RETROSPECTIVE STUDY OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS NOT OPTIMALLY CONTROLLED BY METFORMIN MONOTHERAPY
He J, Neslusan C
Johnson & Johnson Pharmaceutical Services L.L.C, Raritan, NJ, USA |
Drug Use Research I |
| DU1: |
DEMOGRAPHIC RISK FACTORS FOR STROKE RELATED AMBULATORY CARE UTILIZATION: ANALYSIS OF UNITED STATES NATIONAL DATA 2000-2005
Karve S, Levine D, Balkrishnan R
The Ohio State University, Columbus, OH, USA |
| |
|
| DU2: |
DOES COMMUNITY-BASED HEALTH INSURANCE IMPROVE ACCESS TO DRUGS AND HEALTH CARE FOR THE POOREST IN AFRICA?
Souares A1, Savadogo G2, Gnawali DP1, Sauerborn R1
1Heidelberg University, Heidelberg, BadenWürttemberg, Germany, 2Centre de Recherche en Santé de Nouna, Nouna, Kossi, Burkina Faso |
| |
|
| DU3: |
CALIFORNIA WILDFIRES AND THEIR IMPACT ON MEDICATION ACQUISITION
Hutchins DS1, Liberman JN2, Tong W1, Berger JE3
1CVS Caremark, Scottsdale, AZ, USA, 2CVS Caremark Corporation, Hunt Valley, MD, USA, 3CVS|Caremark Inc, Northbrook, IL, USA |
| |
|
| DU4: |
PRESCRIPTION DRUG UTILIZATION AMONG A NATIONALLY REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES WITH HEART FAILURE
Bain KT1, Richardson D2, Liao D2, Diamond J3, Novielli KD2, Goldfarb NI3
1excelleRx, Inc, Philadelphia, PA, USA, 2Jefferson Medical College, Philadelphia, PA, USA, 3Thomas Jefferson University, Philadelphia, PA, USA |
Research on Outcomes Research Methods |
| OM1: |
VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSE THEORY – APPLICATION OF KERNEL REGRESSION
Lin HW1, Pickard AS1, Karabatsos G2, Mahady GB1, Crawford SY1, Popovich NG1
1College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 2College of Education, University of Illinois at Chicago, Chicago, IL, USA |
| |
|
| OM2: |
USING VALUE OF INFORMATION METHODOLOGY TO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE
Willan AR
SickKids Research Insitute, Toronto, ON, Canada |
| |
|
| OM3: |
WAS IT NICE FOR YOU? ESTIMATING SUBGROUP QUALITY OF LIFE TARIFFS FROM CONJOINT ANALYSES: RESULTS FROM A BEST-WORST SCALING STUDY
Flynn TN1, Louviere JJ2, Peters TJ1, Coast J3
1University of Bristol, Bristol, UK, 2University of Technology, Sydney, NSW, Australia, 3University of Birmingham, Birmingham, UK |
| |
|
| OM4: |
LONG-TERM COST-EFFECTIVENESS OF A DIABETES RISK SCORE IN CLINICAL PRACTICE
Sullivan SD1, Garrison LP1, Rinde H2, Kolberg J3, Moler E3, Urdea M4
1University of Washington, Seattle, WA, USA, 2BioBridge Strategies, Binningen, Switzerland, 3Tethys Bioscience Inc, Emeryville, CA, USA, 4Tethys Bioscience, Inc, Emeryville, CA, USA |
| Podium Session VI |
Research in Adherence and Compliance II |
| AC5: |
ORAL ANTIDIABETIC MEDICATION ADHERENCE AND HEALTH CARE COSTS AND UTILIZATION AMONG MEDICAID-ENROLLED TYPE 2 DIABETES PATIENTS NEWLY STARTING MONOTHERAPY
Shenolikar R1, Balkrishnan R2
1Glaxo SmithKline, Columbus, OH, USA, 2The Ohio State University, Columbus, OH, USA |
| |
|
| AC6: |
ASSOCIATION OF NONCOMPLIANCE WITH DIABETES CARE GUIDELINES AND DISEASE BURDEN IN A CALIFORNIA MEDICAID TYPE 2 DIABETES MELLITUS POPULATION
Nichol MB1, Knight TK1, Wu J1, Priest JL2, Cantrell CR2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA |
| |
|
| AC7: |
COMPARING ADHERENCE TO FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED CARE POPULATION
Balu S1, Simko RJ1, Burge RT1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA |
| |
|
| AC8: |
ASSOCIATION OF MEASURES OF MEDICATION ADHERENCE AND SEVERE RELAPSES WITH MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPY
Dickson M1, Kozma C2, Okuda DT3, Fincher C4, Meletiche D4
1University of South Carolina, College of Pharmacy, Columbia, SC, USA, 2University of South Carolina, West Columbia, SC, USA, 3University of California, San Francisco, San Francisco, CA, USA, 4EMD Serono, Inc, Rockland, MA, USA |
Drug Use Research II |
| DU5: |
IMPACT OF FORMULARY RESTRICTIONS ON ADHERENCE TO SECOND GENERATION ANTIPSYCHOTICS
Zeng F1, Leslie RS1, Patel BV1, Chen CC2, Kim E2, Knoth R2, Tran QV3
1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Otsuka America Pharmaceutical Inc, Rockville, MD, USA |
| |
|
| DU6: |
ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
Lafeuille MH1, Lefebvre P1, Bookhart B2, Laliberte F1, Bailey R2, Corral M2, Piech CT2
1Groupe d'analyse, Ltee, Montreal, QC, Canada, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA |
| |
|
| DU7: |
NATIONAL ESTIMATES AND DETERMINANTS OF DEPRESSION AND ANTIDEPRESSANT TREATMENT IN CANCER PATIENTS IN THE UNITED STATES, 2004-2005
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA |
| |
|
| DU8: |
THE EFFECT OF THREE-TIER FORMULARY ADOPTION FOR ALPHA-BLOCKERS ON DRUG UTILIZATION IN THE DEPARTMENT OF DEFENSE
Devine JW, Conrad RC, Tiller KW
Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA |
Infectious Disease Outcomes Research |
| IN1: |
C. ALBICANS AND C. GLABRATA BLOODSTREAM INFECTIONS IN ADULTS: OUTCOMES AND ASSOCIATED COSTS
Grussemeyer CA1, Friedman JY1, Spalding JR2, Benjamin DK3, Moran C3, Reed SD1
1Duke Clinical Research Institute, Durham, NC, USA, 2Astellas Pharma US, Deerfield, IL, USA, 3Duke University Medical Center, Durham, NC, USA |
| |
|
| IN2: |
UPPER RESPIRATORY ILLNESS AND EMPLOYEE PRODUCTIVITY – RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF)
Palmer L1, Nichol KL2, Johnston S1, Mahadevia PJ3, Rousculp MD3
1Thomson Healthcare, Inc, Washington, DC, USA, 2Veterans Affairs Medical Center, Minneapolis, MN, USA, 3MedImmune, Inc, Gaithersburg, MD, USA |
| |
|
| IN3: |
A MICROSIMULATION OF THE COST-EFFECTIVENESS OF MARAVIROC FOR ANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS
Chancellor JV1, Kuehne FC2, Mollon P3, Louie M4, Powderly WG5
1i3 Innovus, Uxbridge, Middlesex, UK, 2PharmacoConsult, Wanzleben-Buch, Germany, 3Pfizer Limited, Sandwich, Kent, UK, 4Pfizer Inc, New York, NY, USA, 5University College Dublin, Dublin, Ireland |
| |
|
| IN4: |
COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA
McGarry LJ1, Merchant S2, Pawar V1, Delong K1, Thompson D1, Akhras K2, Ingham M2, Weinstein MC3
1Innovus Research, Inc, Medford, MA, USA, 2Johnson & Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 3Harvard University, Boston, MA, USA |
Patient-Reported Outcomes Research |
| PR1: |
VARIABILITY OF HEALTH UTILITIES INDEX MARK 3 (HUI3) MEASUREMENTS DURING TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
Rae CS1, Furlong W2, De Pauw S1, Barr RD1, Gelber RD3, Sallan S3
1McMaster University, Hamilton, ON, Canada, 2McMaster University and Health Utilities Inc, Hamilton, ON, Canada, 3Harvard University, Boston, MA, USA |
| |
|
PR2/
PCN75: |
BURDEN OF IMMUNE THROMBOCYTOPENIC PURPURA ON HEALTH-RELATED QUALITY OF LIFE
Mathias S1, Tarantino M2, Guo M3, Gao S3
1Health Outcomes Solutions, Winter Park, FL, USA, 2University of Illinois College of Medicine-Peoria, Peoria, IL, USA, 3Amgen, Thousand Oaks, CA, USA |
| |
|
| PR3: |
IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
Dean BB1, Calimlim B1, Aguilar D1, Sacco P2, Maykut R2, Tinkelman D3
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3National Jewish Medical and Research Center, Denver, CO, USA |
| |
|
| PR4: |
EVALUATION OF IMPACT OF ORAL TOPOTECAN ON HEALTH-RELATED QUALITY OF LIFE IN RELAPSED SMALL CELL LUNG CANCER
Duh MS1, Pickard AS2, Chen L1, Antras L1, Cella D3, Neary MP4, O'Brien ME5
1Analysis Group, Inc, Boston, MA, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Evanston Northwestern Healthcare, Evanston, IL, USA, 4GlaxoSmithKline, Collegeville, PA, USA, 5Royal Marsden Hospital, Sutton, UK |
Women's Health Outcomes Research |
| WH1: |
EXPOSURE TO CONTRAINDICATED AND OTHER POTENTIALLY DANGEROUS MEDICATIONS DURING PREGNANCY: A POPULATION BASED STUDY IN ITALY
Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS
Jefferson Medical College, Philadelphia, PA, USA |
| |
|
| WH2: |
DISABILITY AND ASSOCIATED COSTS AMONG WOMEN WITH EMPLOYER-SPONSORED INSURANCE AND NEWLY DIAGNOSED BREAST CANCER
Meadows E1, Johnston S2, Cao Z3, Foley K4, Pohl G1, Johnston JA1, Ramsey SD5
1Eli Lilly and Company, Indianapolis, IN, USA, 2Thomson Healthcare, Inc, Washington, DC, USA, 3Thomson Healthcare, Cambridge, MA, USA, 4Thomson Medstat, Philadelphia, PA, USA, 5Fred Hutchinson Cancer Research Center, Seattle, WA, USA |
| |
|
| WH3: |
CLINICAL AND ECONOMIC OUTCOMES AMONG WOMEN USING LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS)
Yu AP1, Wu E1, Perrson B1, Chang J2, Costales AC2, Gricar JA3
1Analysis Group, Inc, Boston, MA, USA, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 3Independent Health Care Consultant, New York, NY, USA
|
| |
|
| WH4: |
PROBIOTICS IN PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE SAFETY OF LACTOBACILLUS, BIFIDOBACTERIUM AND SACCHAROMYCES
Dugoua JJ1, Zhu X1, Chen X1, Koren G2, Machado M1, Einarson TR1
1University of Toronto, Toronto, ON, Canada, 2Hospital for Sick Children, Toronto, ON, Canada |
|
